ArticleRadiology case reports2025
Multisystemic impact of autosomal dominant polycystic kidney disease: A case report highlighting renal, hepatic, and neurological involvement.
Article in Radiology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Autosomal Dominant Polycystic Kidney Disease Presenting as a Painless Epigastric Mass: A Case Report.The American journal of case reports · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a case of a 64-year-old male with Autosomal Dominant Polycystic Kidney Disease (ADPKD), characterized by systemic involvement, including renal, hepatic, and neurological complications. The patient presented with persistent micturition difficulties, hematuria, and abdominal pain, compounded by hypertension and chronic obstructive pulmonary disease. Imaging revealed bilateral renal enlargement with hemorrhagic cysts, a kidney stone, and hepatic cysts causing hepatomegaly. Neurological evaluation identified chronic and recent intracerebral hemorrhages associated with poorly controlled hypertension, underscoring ADPKD's multisystem impact. ADPKD, caused by PKD1 or PKD2 mutations, often leads to progressive renal dysfunction, hypertension, and extrarenal manifestations such as hepatic cysts and intracranial aneurysms. Advances like tolvaptan demonstrate efficacy in slowing renal disease progression, while somatostatin analogs offer promise for hepatic cyst management. This case emphasizes the necessity of a multidisciplinary approach, including strict blood pressure control, regular imaging, and pharmacological intervention, to address ADPKD's complexities and optimize patient outcomes. Early diagnosis and vigilant monitoring remain crucial for preventing complications and enhancing quality of life. This report underscores the importance of integrated care in managing ADPKD, highlighting emerging therapies and the ongoing need for personalized treatment strategies in such challenging cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.